BlackRock Virginia Municipal Bond Trust (BHV)
NYSE NYSE Primary 
Biohaven: Nice Pipeline Momentum, But Its Runway Is A Risk
Biohaven's pipeline is now more focused after having to narrow down its R&D efforts to other assets. Today, I think opakalim's pivotal epilepsy readout is probably the most important near-term catalyst that could validate their pipeline. They also have interesting, albeit early, positive findings with BHV-1300 and BHV-1400 for their degrader platform.
Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study Initiations
Biohaven (BHVN) is upgraded from "Hold" to "Buy," driven by FDA regulatory shifts and strong biomarker data for its protein degrader pipeline. The company is set to initiate pivotal studies for BHV-1300 in Graves' Disease and BHV-1400 in IgA Nephropathy in mid-2026, targeting large unmet markets. Phase 1b data show over 80% reduction in pathogenic TSHR-IgG1 for BHV-1300 and over 60% Gd-IgA1 reduction for BHV-1400, with safety advantages over competitors.
